OBP Ondine Biomed

 
TIDMOBP 
 
FDA Accepts Filing of Ondine's Pre-Market Approval (PMA) Application for Periowave(TM) Photodisinfection System 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
March 17, 2010 
 
FDA Accepts Filing of Ondine's Pre-Market Approval (PMA) Application for Periowave(TM) Photodisinfection System 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 17, 2010) - Ondine Biopharma Corporation (the "Company" or 
"Ondine") (TSX:OBP)(AIM:OBP), a medical technology company developing photodisinfection-based products, 
announces that the U.S. Food and Drug Administration (FDA) has formally accepted for filing the Company's Pre- 
Market Approval (PMA) application for the Periowave(TM) Photodisinfection System for the treatment of chronic 
periodontitis in adults as an adjunct to standard methods of care. The FDA's action means that the PMA 
application is sufficiently complete and ready for substantive review. 
 
"The acceptance of the PMA submission is a welcome step forward for Ondine and our business partner, Periowave 
Dental Technologies, Inc.," said Carolyn Cross, Chairman & CEO of Ondine. "One of Ondine's key priorities is to 
obtain regulatory clearance in the United States for the marketing of Periowave(TM), the first commercial 
application of the Company's photodisinfection technology." 
 
About Periowave(TM) 
 
Periowave(TM) is a non-antibiotic photodisinfection system for the dental market developed by Ondine that 
utilizes a low-intensity diode laser and a wavelength-specific, light-activated photosensitive compound which, 
when used in conjunction with standard methods of dental care, reduces the symptoms of chronic periodontitis. 
The photosensitizing solution is topically applied to the treatment site and preferentially stains pathogenic 
microbes present at the site. Once exposed to the Periowave(TM) laser, these pathogens and their associated 
virulence factors are rapidly destroyed, significantly improving clinical outcomes. The photodisinfection 
process is designed to avoid the development of antibiotic resistance. 
 
The Photodisinfection technologies were developed in the 1980's by Professor Michael Wilson and colleagues at 
the Eastman Dental Institute, University College London. Periowave(TM) is currently approved in Canada and the 
European Union for the treatment of a number of gum diseases, including periodontitis, peri-implantitis, and 
peri-mucositis. In June of 2009, Ondine sold its dental healthcare business to Periowave Dental Technologies, 
Inc. (PDT). Under the terms of the sale, the Company is entitled to receive royalties and milestone payments 
based on sales of the Periowave(TM) Photodisinfection System by PDT, Ondine continues to be the manufacturer of 
the product and is responsible for obtaining regulatory clearance for marketing of the product in the United 
States. 
 
For more information about the FDA & the submission review process, please visit the FDA website at: 
www.fda.gov. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the 
formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, 
with a research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebiopharma.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
(604) 669-0555 
ccross@ondinebiopharma.com 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Adams Ltd. 
Nominated Adviser 
Ryan Gaffney 
+4420 7050 6500 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
 
Ondine Biopharma Corporation 
 

Grafico Azioni Ondine Biomed (LSE:OBP)
Storico
Da Mag 2024 a Mag 2024

Grafico Azioni Ondine Biomed (LSE:OBP)
Storico
Da Mag 2023 a Mag 2024